房颤患者半剂量与全剂量艾多沙班的随机双盲比较:14,014例分析
该研究为ENGAGE AF-TIMI 48试验的预设分析,比较房颤患者接受低剂量艾多沙班方案(LDER,30mg每日一次,部分患者减至15mg)与高剂量方案(HDER,60mg每日一次,部分患者减至30mg)的净临床结局。结果显示LDER的主要净临床结局(卒中/体循环栓塞、大出血、死亡)低于HDER(7.26% vs 8.01%;HR 0.90;95%CI 0.84-0.98;P=0.014),但卒中/体循环栓塞风险更高(2.04% vs 1.56%;HR 1.31;95%CI 1.12-1.52;P<0.001),而大出血、颅内出血等显著更少。结论提示结果有助于个体化选择剂量,但HDER仍是房颤卒中预防的标准治疗。
要点
- LDER主要净临床结局低于HDER(7.26% vs 8.01%;HR 0.90;P=0.014)。
- LDER卒中/体循环栓塞风险高于HDER(2.04% vs 1.56%;HR 1.31;P<0.001)。
- LDER大出血、颅内出血、重大胃肠道出血及危及生命出血均显著少于HDER。
核心结论
- 在ENGAGE AF-TIMI 48试验中,LDER相比HDER降低了主要净临床结局,但次要和三级净临床结局相似。
- 结果可能有助于医生基于证据个体化选择艾多沙班剂量,但获批的HDER仍是房颤卒中预防的标准治疗。
研究设计与样本
- ENGAGE AF-TIMI 48试验的预设分析,比较接受LDER与HDER的患者。
- LDER为30mg每日一次,选择性患者减至15mg;HDER为60mg每日一次,选择性患者减至30mg。
主要发现
- 主要净临床结局(卒中/体循环栓塞、大出血、死亡)LDER组为7.26%,HDER组为8.01%(HR 0.90;95%CI 0.84-0.98;P=0.014)。
- 卒中/体循环栓塞LDER组为2.04%,HDER组为1.56%(HR 1.31;95%CI 1.12-1.52;P<0.001)。
- 大出血、颅内出血、重大胃肠道出血和危及生命出血在LDER组显著少于HDER组。
- 次要净临床结局(致残性卒中、危及生命出血或全因死亡)和三级净临床结局(卒中、体循环栓塞、危及生命出血或全因死亡)在两种剂量方案间相似。
临床怎么用
- 临床可根据患者卒中与出血风险个体化选择艾多沙班剂量,但HDER仍是房颤卒中预防的标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, the lower dose edoxaban regimen (LDER) and the higher dose edoxaban regimen (HDER) were noninferior to well-managed warfarin for stroke prevention in atrial fibrillation. OBJECTIVES: The objective of the present analysis of the ENGAGE AF TIMI-48 trial was to comprehensively compare the net clinical outcome (NCO) of LDER (30 mg once daily, dose reduced to 15 mg in selective patients) versus HDER (60 mg once daily, dose reduced to 30 mg in selective patients). METHODS: This study performed a pre-specified analysis of the ENGAGE AF-TIMI 48 trial, comparing patients on LDER versus HDER. RESULTS: The pre-defined primary NCO (stroke/systemic embolism [SEE], major bleeding, death) was less frequent with LDER (7.26% vs. 8.01%; hazard ratio: 0.90; 95% confidence interval: 0.84 to 0.98; p = 0.014). The secondary (disabling stroke, life-threatening bleeding, or all-cause mortality) and tertiary pre-defined NCOs (stroke, SEE, life-threatening bleeding, or all-cause mortality) were similar between the 2 dosing regimens. Patients randomized to LDER versus HDER had a significantly higher risk of stroke/SEE (2.04% vs. 1.56%; hazard ratio: 1.31; 95% confidence interval: 1.12 to 1.52; p < 0.001). Conversely, major bleeding, intracranial hemorrhage, major gastrointestinal bleeding, and life-threatening bleeding occurred significantly less frequently with LDER compared with those of HDER. These findings were supported by multiple pharmacokinetic findings. CONCLUSIONS: In the ENGAGE AF-TIMI 48 trial, the primary NCO was reduced with LDER versus HDER, whereas the secondary and tertiary NCOs were similar between the 2 dosing regimens. These results may aid physicians in evidence-based individualization of edoxaban dosing. However, the approved HDER remains the standard therapy among the available edoxaban dosing regimens for stroke prevention in atrial fibrillation. (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48 [ENGAGE AF-TIMI 48]; NCT00781391).
引用
- Steffel J, Ruff CT, Yin O, et al. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. J Am Coll Cardiol. 2021. PMID: 33663737. doi:10.1016/j.jacc.2020.12.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。